Open AccessCancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities
Author(s) -
Fei Liu,
Tesfaldet H. Hidru,
Ruiyuan Gao,
Yajuan Lin,
Ying Liu,
F. Fang,
Jiwei Liu,
Huihua Li,
Xiaolei Yang,
Yunlong Xia
Publication year - 2020
Publication title -
journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.249
H-Index - 172
eISSN - 1473-5598
pISSN - 0263-6352
DOI - 10.1097/hjh.0000000000002277
Subject(s) - medicine , cancer , lung cancer , colorectal cancer , thyroid cancer , oncology , risk factor , atrial fibrillation
Recent studies have reported the prevalence of cardiovascular diseases (CVDs) among cancer patients following the use of the vascular endothelial growth factor (VEGF) signaling inhibitors. However, data for patients with a history of cancer before active cancer treatment are lacking. This study aims to investigate the distribution of CVD-related comorbidities before cancer treatment in potential VEGF antagonists candidates.